Immediate Impact
2 from Science/Nature 52 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Theranostic Fluorescent Probes
2024 Standout
Works of Assunta Sgambato being referenced
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
2017
ALK inhibitors in the treatment of advanced NSCLC
2013
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Assunta Sgambato | 406 | 436 | 286 | 31 | 727 | |
| Francesca Casaluce | 450 | 505 | 318 | 37 | 823 | |
| Sven Gogov | 399 | 335 | 287 | 25 | 768 | |
| Giovanni Palazzolo | 464 | 520 | 204 | 46 | 770 | |
| Junko Hamamoto | 529 | 441 | 400 | 27 | 792 | |
| Caicun Zhou | 372 | 416 | 186 | 35 | 668 | |
| Youwei Bi | 293 | 261 | 212 | 24 | 719 | |
| Silvia Paola Corona | 348 | 383 | 223 | 42 | 669 | |
| Jie Xu | 415 | 279 | 319 | 24 | 739 | |
| Joseph Chen | 507 | 433 | 234 | 27 | 762 | |
| Pietro De Placido | 376 | 461 | 229 | 49 | 764 |
All Works
Loading papers...